Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Stock Exchange of Hong Kong  >  Wuxi Biologics Cayman Inc    2269   KYG970081090

WUXI BIOLOGICS CAYMAN INC

(2269)
  Report  
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Researchers at WuXi Biologics Detail Findings in Antibodies (Monitoring removal of hole-hole homodimer by analytical hydrophobic interaction chromatography in purifying a bispecific antibody): Immunology - Antibodies

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 05:32pm EDT

2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at China Business Day -- Data detailed on Immunology - Antibodies have been presented. According to news reporting originating from Shanghai, People’s Republic of China, by NewsRx correspondents, research stated, “Despite the use of knobs-into-holes (KiH) strategy to promote heterodimerization in recombinant production of bispecific antibody (bsAb), homodimer (especially the hole-hole homodimer) can still be generated in small amount. This by-product needs to be removed by downstream process.”

Our news editors obtained a quote from the research from WuXi Biologics, “However, as homodimer and the target bsAb are usually very close in size, these two species may not be readily differentiated using size-exclusion chromatography-high performance liquid chromatography (SEC-HPLC). Thus, method other than SEC-HPLC needs to be developed to monitor removal of this by-product.”

According to the news editors, the research concluded: “Here, through a case study we demonstrate that analytical hydrophobic interaction chromatography (HIC) is a powerful tool for quantitatively monitoring removal of hole-hole homodimer in bsAb purification.”

For more information on this research see: Monitoring removal of hole-hole homodimer by analytical hydrophobic interaction chromatography in purifying a bispecific antibody. Protein Expression and Purification, 2019;164():105457. Protein Expression and Purification can be contacted at: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Protein Expression and Purification - http://www.journals.elsevier.com/protein-expression-and-purification/)

The news editors report that additional information may be obtained by contacting Y. Li, Technology and Process Development (TPD), WuXi Biologics, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, People’s Republic of China. Additional authors for this research include J. Han, G. Guo, Q. Wang, Y. Wang and Y. Li.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.pep.2019.105457. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Protein Expression and Purification is: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Copyright © 2019 NewsRx LLC, China Business Day, source Geographic Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on WUXI BIOLOGICS CAYMAN INC
06/26WUXI BIOLOGICS CAYMAN : adds ADC commercial manufacturing at WuXi city facility
AQ
06/11WUXI BIOLOGICS CAYMAN : Jacobs Wins Contract to Provide Construction Services fo..
AQ
05/25WUXI BIOLOGICS CAYMAN : in $3bn deal to manufacture 'first of its kind' vaccine
AQ
05/22WUXI BIOLOGICS CAYMAN : Signed Letter of Intent for Long-Term Vaccine Manufactur..
AQ
05/17WUXI BIOLOGICS CAYMAN : Commenced Construction of a 48,000 L Integrated Manufact..
AQ
05/17WUXI BIOLOGICS CAYMAN : to build 1.3m-sq-ft manufacturing centre
AQ
04/17WUXI BIOLOGICS CAYMAN : I-Mab Biopharma and WuXi Biologics Announce Long-term St..
AQ
04/10WUXI BIOLOGICS CAYMAN : and NBE-Therapeutics Announce Comprehensive ADC Developm..
AQ
03/27WUXI BIOLOGICS CAYMAN : Receives "Asia`s Best CMO of 2018" Award from IMAPAC
AQ
03/23WUXI BIOLOGICS CAYMAN : PharmaTech subsidiaries hit regulatory and manufacturing..
AQ
More news
Financials (CNY)
Sales 2019 3 922 M
EBIT 2019 1 097 M
Net income 2019 966 M
Finance 2019 1 633 M
Yield 2019 -
P/E ratio 2019 97,7x
P/E ratio 2020 65,7x
EV / Sales2019 23,2x
EV / Sales2020 16,0x
Capitalization 92 620 M
Chart WUXI BIOLOGICS CAYMAN INC
Duration : Period :
Wuxi Biologics Cayman Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 90,56  CNY
Last Close Price 74,06  CNY
Spread / Highest target 45,6%
Spread / Average Target 22,3%
Spread / Lowest Target 7,31%
EPS Revisions
Managers
NameTitle
Zhi Sheng Chen Chief Executive Officer & Executive Director
Ge Li Non-Executive Chairman
Shao Hua Lu-Wong Chief Financial Officer
Weichang Zhou Executive Director, Chief Technology Officer & SVP
Edward Hu Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
WUXI BIOLOGICS CAYMAN INC13 039
CSL LIMITED22.81%70 445
BIOGEN INC.-21.67%43 478
ALEXION PHARMACEUTICALS13.86%25 266
GRIFOLS26.38%19 400
SAMSUNG BIOLOGICS CO LTD--.--%15 497